
Steven A Lubitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6988642/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020, 581, 434-443.	27.8	6,140
2	Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics, 2018, 50, 1219-1224.	21.4	2,111
3	50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet, The, 2015, 386, 154-162.	13.7	1,148
4	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke subtypes. Nature Genetics, 2018, 50, 524-537.	21.4	1,124
5	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature, 2021, 590, 290-299.	27.8	1,069
6	Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGEâ€AF Consortium. Journal of the American Heart Association, 2013, 2, e000102.	3.7	601
7	Atrial Fibrillation Begets Heart Failure and Vice Versa. Circulation, 2016, 133, 484-492.	1.6	561
8	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	21.4	552
9	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	27.8	544
10	Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nature Genetics, 2012, 44, 670-675.	21.4	533
11	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 2020, 11, 163.	12.8	466
12	Common variants in KCNN3 are associated with lone atrial fibrillation. Nature Genetics, 2010, 42, 240-244.	21.4	438
13	Genome-wide association study of PR interval. Nature Genetics, 2010, 42, 153-159.	21.4	400
14	Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nature Genetics, 2009, 41, 879-881.	21.4	363
15	Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nature Metabolism, 2020, 2, 1135-1148.	11.9	327
16	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Research, 2015, 25, 305-315.	5.5	313
17	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nature Genetics, 2017, 49, 946-952.	21.4	279
18	Association Between Familial Atrial Fibrillation and Risk of New-Onset Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2010, 304, 2263.	7.4	257

#	Article	IF	CITATIONS
19	Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk. JAMA Cardiology, 2016, 1, 55.	6.1	249
20	Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ: British Medical Journal, 2018, 361, k1453.	2.3	232
21	Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome sequences improves imputation quality and detection of rare variant associations in admixed African and Hispanic/Latino populations. PLoS Genetics, 2019, 15, e1008500.	3.5	203
22	Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation. Circulation, 2018, 137, 1027-1038.	1.6	196
23	Integrating Genetic, Transcriptional, and Functional Analyses to Identify 5 Novel Genes for Atrial Fibrillation. Circulation, 2014, 130, 1225-1235.	1.6	183
24	Frequency of Cardiac Rhythm Abnormalities in a Half Million Adults. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006273.	4.8	159
25	Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. Nature Genetics, 2022, 54, 263-273.	21.4	156
26	Long-Term Outcomes of Secondary Atrial Fibrillation in the Community. Circulation, 2015, 131, 1648-1655.	1.6	154
27	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm, 2021, 18, e1-e50.	0.7	151
28	B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace, 2014, 16, 1426-1433.	1.7	144
29	Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2018, 320, 2354.	7.4	144
30	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score. Circulation, 2020, 141, 616-623.	1.6	143
31	Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. Nature Communications, 2020, 11, 2254.	12.8	140
32	Independent Susceptibility Markers for Atrial Fibrillation on Chromosome 4q25. Circulation, 2010, 122, 976-984.	1.6	137
33	Novel Genetic Markers Associate With Atrial Fibrillation Risk in Europeans and Japanese. Journal of the American College of Cardiology, 2014, 63, 1200-1210.	2.8	127
34	Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation PatientsÂatÂRisk for Stroke. Journal of the American College of Cardiology, 2016, 67, 2913-2923.	2.8	119
35	Atrial Fibrillation in Congestive Heart Failure. Heart Failure Clinics, 2010, 6, 187-200.	2.1	112
36	Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery. Circulation, 2019, 139, 489-501.	1.6	109

#	Article	IF	CITATIONS
37	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	1.7	108
38	Galectin 3 and incident atrial fibrillation in the community. American Heart Journal, 2014, 167, 729-734.e1.	2.7	101
39	Blood Lipids and the Incidence of Atrial Fibrillation: The Multiâ€Ethnic Study of Atherosclerosis and the Framingham Heart Study. Journal of the American Heart Association, 2014, 3, e001211.	3.7	99
40	ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation. Circulation, 2022, 145, 122-133.	1.6	99
41	Common Genetic Variants and Response to Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 296-302.	4.8	98
42	Genetic Obesity and the Risk of Atrial Fibrillation. Circulation, 2017, 135, 741-754.	1.6	96
43	Twelve–Single Nucleotide Polymorphism Genetic Risk Score Identifies Individuals at Increased Risk for Future Atrial Fibrillation and Stroke. Stroke, 2014, 45, 2856-2862.	2.0	95
44	Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nature Communications, 2017, 8, 15805.	12.8	95
45	Deep learning enables genetic analysis of the human thoracic aorta. Nature Genetics, 2022, 54, 40-51.	21.4	90
46	Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 75, 2769-2780.	2.8	88
47	Genetic Risk Prediction of Atrial Fibrillation. Circulation, 2017, 135, 1311-1320.	1.6	87
48	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
49	Monogenic and Polygenic Contributions to Atrial Fibrillation Risk. Circulation Research, 2020, 126, 200-209.	4.5	79
50	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.7	78
51	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. Europace, 2018, 20, 1399-1421.	1.7	75
52	Development of a clinical polygenic risk score assay and reporting workflow. Nature Medicine, 2022, 28, 1006-1013.	30.7	74
53	Relations of Arterial Stiffness and Brachial Flow–Mediated Dilation With New-Onset Atrial Fibrillation. Hypertension, 2016, 68, 590-596.	2.7	72
54	Heritability of Atrial Fibrillation. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	72

#	Article	IF	CITATIONS
55	PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity. Nature Communications, 2018, 9, 2904.	12.8	71
56	A comparison of the CHARGE–AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. American Heart Journal, 2016, 178, 45-54.	2.7	70
57	A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. Nature Genetics, 2021, 53, 1504-1516.	21.4	69
58	Genetics of Atrial Fibrillation: State of the Art in 2017. Heart Lung and Circulation, 2017, 26, 894-901.	0.4	68
59	Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank. Nature Genetics, 2022, 54, 240-250.	21.4	68
60	Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation. JAMA Cardiology, 2019, 4, 144.	6.1	64
61	Genetics of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 291-299.	4.8	62
62	Novel Mutation in <i>FLNC</i> (Filamin C) Causes Familial Restrictive Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	62
63	Atrial Fibrillation Patterns and Risks of Subsequent Stroke, Heart Failure, or Death in the Community. Journal of the American Heart Association, 2013, 2, e000126.	3.7	61
64	Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm, 2016, 13, 233-240.	0.7	61
65	Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: The Fitbit heart study. American Heart Journal, 2021, 238, 16-26.	2.7	61
66	A Functional Variant Associated with Atrial Fibrillation Regulates PITX2c Expression through TFAP2a. American Journal of Human Genetics, 2016, 99, 1281-1291.	6.2	59
67	Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction. Nature Communications, 2020, 11, 2542.	12.8	59
68	Population-Based Screening for Atrial Fibrillation. Circulation Research, 2020, 127, 143-154.	4.5	59
69	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
70	Korean Atrial Fibrillation (AF) Network: Genetic Variants for AF Do Not Predict Ablation Success. Journal of the American Heart Association, 2015, 4, e002046.	3.7	56
71	Stroke as the Initial Manifestation of Atrial Fibrillation. Stroke, 2017, 48, 490-492.	2.0	56
72	Development and Validation of a Prediction Model for Atrial Fibrillation Using Electronic Health Records. JACC: Clinical Electrophysiology, 2019, 5, 1331-1341.	3.2	56

#	Article	IF	CITATIONS
73	Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. European Heart Journal, 2015, 36, 2780-2789.	2.2	55
74	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
75	Novel Loci Associated With PR Interval in a Genome-Wide Association Study of 10 African American Cohorts. Circulation: Cardiovascular Genetics, 2012, 5, 639-646.	5.1	48
76	Methylome-wide Association Study of Atrial Fibrillation in Framingham Heart Study. Scientific Reports, 2017, 7, 40377.	3.3	48
77	Trajectories of Risk Factors and Risk of New-Onset Atrial Fibrillation in the Framingham Heart Study. Hypertension, 2016, 68, 597-605.	2.7	46
78	Challenges in the classification of atrial fibrillation. Nature Reviews Cardiology, 2010, 7, 451-460.	13.7	44
79	Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial. Circulation, 2022, 145, 946-954.	1.6	43
80	Proteomics Profiling and Risk of Newâ€Onset Atrial Fibrillation: Framingham Heart Study. Journal of the American Heart Association, 2019, 8, e010976.	3.7	42
81	Research Priorities in Atrial Fibrillation Screening. Circulation, 2021, 143, 372-388.	1.6	42
82	Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. American Heart Journal, 2018, 200, 24-31.	2.7	41
83	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. Journal of Arrhythmia, 2018, 34, 99-123.	1.2	41
84	Integrative Omics Approach to Identifying Genes Associated With Atrial Fibrillation. Circulation Research, 2020, 126, 350-360.	4.5	41
85	Genetic Factors Influencing Warfarin Dose in Blackâ€African Patients: A Systematic Review and Metaâ€Analysis. Clinical Pharmacology and Therapeutics, 2020, 107, 1420-1433.	4.7	40
86	Atrial Fibrillation Genetics: Is There a Practical Clinical Value Now or in the Future?. Canadian Journal of Cardiology, 2016, 32, 1300-1305.	1.7	39
87	Wearing Your Heart on Your Sleeve: the Future of Cardiac Rhythm Monitoring. Current Cardiology Reports, 2019, 21, 158.	2.9	39
88	Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. Nature Communications, 2020, 11, 6417.	12.8	39
89	Accelerometer-derived physical activity and risk of atrial fibrillation. European Heart Journal, 2021, 42, 2472-2483.	2.2	38
90	Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study. Journal of the American Heart Association, 2017, 6, .	3.7	37

#	Article	IF	CITATIONS
91	Initial Precipitants and Recurrence of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007716.	4.8	37
92	Effectiveness of cardiac resynchronization therapy in mild congestive heart failure: systematic review and metaâ€analysis of randomized trials. European Journal of Heart Failure, 2010, 12, 360-366.	7.1	36
93	A Simple and Portable Algorithm for Identifying Atrial Fibrillation in the Electronic Medical Record. American Journal of Cardiology, 2016, 117, 221-225.	1.6	36
94	Sex differences in inflammatory markers in patients hospitalized with COVID-19 infection: Insights from the MGH COVID-19 patient registry. PLoS ONE, 2021, 16, e0250774.	2.5	36
95	Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes. Neurology: Genetics, 2018, 4, e293.	1.9	35
96	Epigenetic Age and the Risk of Incident Atrial Fibrillation. Circulation, 2021, 144, 1899-1911.	1.6	35
97	Whole Exome Sequencing in Atrial Fibrillation. PLoS Genetics, 2016, 12, e1006284.	3.5	35
98	Genomic basis of atrial fibrillation. Heart, 2018, 104, 201-206.	2.9	34
99	Genetic analysis of right heart structure and function in 40,000 people. Nature Genetics, 2022, 54, 792-803.	21.4	34
100	Atrial Fibrillation Genetic Risk and Ischemic Stroke Mechanisms. Stroke, 2017, 48, 1451-1456.	2.0	33
101	Diminished <i>PRRX1</i> Expression Is Associated With Increased Risk of Atrial Fibrillation and Shortening of the Cardiac Action Potential. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	33
102	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
103	The role of obesity in inflammatory markers in COVID-19 patients. Obesity Research and Clinical Practice, 2021, 15, 96-99.	1.8	32
104	Accuracy and Usability of a Novel Algorithm for Detection of Irregular Pulse Using a Smartwatch Among Older Adults: Observational Study. JMIR Cardio, 2019, 3, e13850.	1.7	32
105	Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. European Heart Journal, 2022, 43, 3041-3052.	2.2	32
106	Protein Biomarkers and Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007607.	4.8	31
107	Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants. American Journal of Cardiology, 2017, 120, 786-791.	1.6	30
108	Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007676.	4.8	30

#	Article	IF	CITATIONS
109	Performance of Atrial Fibrillation Risk Prediction Models in Over 4 Million Individuals. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008997.	4.8	30
110	Next-generation sequencing for the diagnosis of cardiac arrhythmia syndromes. Heart Rhythm, 2015, 12, 1062-1070.	0.7	29
111	Discovery of novel heart rate-associated loci using the Exome Chip. Human Molecular Genetics, 2017, 26, 2346-2363.	2.9	29
112	Survey of current perspectives on consumer-available digital health devices for detecting atrial fibrillation. Cardiovascular Digital Health Journal, 2020, 1, 21-29.	1.3	28
113	Cohort design and natural language processing to reduce bias in electronic health records research. Npj Digital Medicine, 2022, 5, 47.	10.9	28
114	Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart) Tj ETQq0 0 0 rgB	[/Overloch	ء 10 Tf 50 54 27
115	ExomeChip-Wide Analysis of 95 626 Individuals Identifies 10 Novel Loci Associated With QT and JT Intervals. Circulation Genomic and Precision Medicine, 2018, 11, e001758.	3.6	27
116	Common Coding Variants in <i>SCN10A</i> Are Associated With the Nav1.8 Late Current and Cardiac Conduction. Circulation Genomic and Precision Medicine, 2018, 11, e001663.	3.6	26
117	Deep Learning to Predict Cardiac Magnetic Resonance–Derived Left Ventricular Mass and Hypertrophy From 12-Lead ECGs. Circulation: Cardiovascular Imaging, 2021, 14, e012281.	2.6	26
118	Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. European Heart Journal, 2022, 43, 1668-1680.	2.2	25
119	Targeted sequencing in candidate genes for atrial fibrillation: The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Targeted Sequencing Study. Heart Rhythm, 2014, 11, 452-457.	0.7	24
120	Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. Journal of General Internal Medicine, 2018, 33, 2070-2077.	2.6	24
121	Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trial. American Heart Journal, 2019, 215, 147-156.	2.7	24
122	A Genetic Risk Score for Atrial Fibrillation Predicts the Response to Catheter Ablation. Korean Circulation Journal, 2019, 49, 338.	1.9	24
123	Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes. American Journal of Human Genetics, 2022, 109, 81-96.	6.2	24
124	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	1.2	24
125	Whole Blood Gene Expression and Atrial Fibrillation: The Framingham Heart Study. PLoS ONE, 2014, 9, e96794.	2.5	23
126	Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverterâ€defibrillator systems: Results of the SENSE trial. Journal of Cardiovascular Electrophysiology, 2019, 30, 1994-2001.	1.7	23

#	Article	IF	CITATIONS
127	Effect of <i><scp>CYP</scp>4F2</i> , <i><scp>VKORC</scp>1</i> , and <i><scp>CYP</scp>2C9</i> in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
128	Titin Truncating Variants in Adults Without Known Congestive HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1239-1241.	2.8	22
129	Automated Electronic Phenotyping of Cardioembolic Stroke. Stroke, 2021, 52, 181-189.	2.0	22
130	Massachusetts general hospital Covid-19 registry reveals two distinct populations of hospitalized patients by race and ethnicity. PLoS ONE, 2020, 15, e0244270.	2.5	22
131	Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank. JAMA Cardiology, 2022, 7, 715.	6.1	22
132	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. Heart Rhythm, 2018, 15, e37-e60.	0.7	21
133	Understanding the Link Between Obesity and Severe COVID-19 Outcomes: Causal Mediation by Systemic Inflammatory Response. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e698-e707.	3.6	21
134	Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. American Heart Journal, 2018, 195, 50-59.	2.7	20
135	Relation of Orthostatic Hypotension With New-Onset Atrial Fibrillation (From the Framingham Heart) Tj ETQq1 I	1 0.784314 1.84314	rgBT /Overlo
136	Response by Aragam et al to Letter Regarding Article, "Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery― Circulation, 2019, 140, e7-e8.	1.6	20
137	Effect of a Multidisciplinary Approach for the Management of Patients With Atrial Fibrillation in the Emergency Department on Hospital Admission Rate and Length of Stay. American Journal of Cardiology, 2016, 118, 64-71.	1.6	19
138	Common and Rare Coding Genetic Variation Underlying the Electrocardiographic PR Interval. Circulation Genomic and Precision Medicine, 2018, 11, e002037.	3.6	19
139	Non–Vitamin K Antagonist Oral Anticoagulant vs Warfarin for Post Cardiac Surgery Atrial Fibrillation. Annals of Thoracic Surgery, 2021, 112, 1392-1401.	1.3	18
140	Validation of Polygenic Scores for QT Interval in Clinical Populations. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
141	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Journal of Arrhythmia, 2021, 37, 481-534.	1.2	17
142	Association Between Frailty and Atrial Fibrillation in Older Adults: The Framingham Heart Study Offspring Cohort. Journal of the American Heart Association, 2021, 10, e018557.	3.7	17
143	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. Nature Communications, 2021, 12, 2182.	12.8	17
144	Impact of a Multidisciplinary Treatment Pathway for Atrial Fibrillation in the Emergency Department on Hospital Admissions and Length of Stay: Results of a Multi enter Study. Journal of the American Heart Association, 2019, 8, e012656.	3.7	16

#	Article	IF	CITATIONS
145	Genetic Determinants of Electrocardiographic P-Wave Duration and Relation to Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2020, 13, 387-395.	3.6	16
146	Gene-gene Interaction Analyses for Atrial Fibrillation. Scientific Reports, 2016, 6, 35371.	3.3	15
147	Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium. Scientific Reports, 2017, 7, 11303.	3.3	15
148	Atrial Fibrillation Risk and Discrimination of Cardioembolic From Noncardioembolic Stroke. Stroke, 2020, 51, 1396-1403.	2.0	15
149	Association Between Leukocyte Telomere Length and the Risk of Incident Atrial Fibrillation: The Framingham Heart Study. Journal of the American Heart Association, 2017, 6, .	3.7	14
150	Epigenetic Analyses of Human Left Atrial Tissue Identifies Gene Networks Underlying Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2020, 13, e003085.	3.6	14
151	Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005918.	2.2	14
152	Monogenic and Polygenic Contributions to QTc Prolongation in the Population. Circulation, 2022, 145, 1524-1533.	1.6	14
153	Clinical and genetic evaluation after sudden cardiac arrest. Journal of Cardiovascular Electrophysiology, 2020, 31, 570-578.	1.7	13
154	Genetically Determined Birthweight Associates With Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2020, 13, e002553.	3.6	13
155	Predictive Accuracy of a Clinical and Genetic Risk Model for Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2021, 14, e003355.	3.6	13
156	2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders. Heart Rhythm, 2022, 19, e61-e120.	0.7	13
157	Trends in Consumer Wearable Devices With Cardiac Sensors in a Primary Care Cohort. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	2.2	13
158	Refining the Association Between Body Mass Index and Atrial Fibrillation: Gâ€Formula and Restricted Mean Survival Times. Journal of the American Heart Association, 2019, 8, e013011.	3.7	12
159	Stroke risk in AF: do AF patterns matter?. European Heart Journal, 2010, 31, 908-910.	2.2	11
160	Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation. American Heart Journal, 2016, 176, 100-106.	2.7	11
161	Periprocedural Antibiotic Prophylaxis for Cardiac Implantable Electrical Device Procedures. JACC: Clinical Electrophysiology, 2017, 3, 632-634.	3.2	11
162	Factors Associated with Anticoagulation Delay Following New-Onset Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 1316-1321.	1.6	11

#	Article	IF	CITATIONS
163	Genetic Link Between Arterial Stiffness and Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2019, 12, e002453.	3.6	11
164	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	3.1	11
165	Relations between plasma microRNAs, echocardiographic markers of atrial remodeling, and atrial fibrillation: Data from the Framingham Offspring study. PLoS ONE, 2020, 15, e0236960.	2.5	10
166	Experience With Wearable Cardioverter-Defibrillators at 2ÂAcademicÂMedical Centers. JACC: Clinical Electrophysiology, 2018, 4, 231-239.	3.2	9
167	NExUS-Heart: Novel examinations using smart technologies for heart health—Data sharing from commercial wearable devices and telehealth engagement in participants with or at risk of atrial fibrillation. Cardiovascular Digital Health Journal, 2021, 2, 256-263.	1.3	9
168	Biventricular pacing: more is better!. European Heart Journal, 2015, 36, 407-409.	2.2	8
169	Systemic Embolic Events (SEE) in Atrial Fibrillation. Circulation, 2015, 132, 787-789.	1.6	8
170	Serum brain-derived neurotrophic factor and risk of atrial fibrillation. American Heart Journal, 2017, 183, 69-73.	2.7	8
171	Reâ€CHARGEâ€AF: Recalibration of the CHARGEâ€AF Model for Atrial Fibrillation Risk Prediction in Patients With Acute Stroke. Journal of the American Heart Association, 2021, 10, e022363.	3.7	8
172	Resting heart rate and incident atrial fibrillation: A stratified Mendelian randomization in the AFGen consortium. PLoS ONE, 2022, 17, e0268768.	2.5	8
173	Personalized medicine and atrial fibrillation: will it ever happen?. BMC Medicine, 2012, 10, 155.	5.5	7
174	Rare Coding Variants Associated With Electrocardiographic Intervals Identify Monogenic Arrhythmia Susceptibility Genes: A Multi-Ancestry Analysis. Circulation Genomic and Precision Medicine, 2021, 14, e003300.	3.6	7
175	The Value of Rare Genetic Variation in the Prediction of Common Obesity in European Ancestry Populations. Frontiers in Endocrinology, 2022, 13, 863893.	3.5	7
176	Recent Trends In Oral Anticoagulant Use And Post-Discharge Complications Among Atrial Fibrillation Patients With Acute Myocardial Infarction. Journal of Atrial Fibrillation, 2018, 10, 1749.	0.5	6
177	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	3.6	6
178	Robust, flexible, and scalable tests for Hardy–Weinberg equilibrium across diverse ancestries. Genetics, 2021, 218, .	2.9	6
179	Management of Congenital Long-QT Syndrome: Commentary From the Experts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009726.	4.8	5
180	Rationale and Design of the Randomized Controlled Trial of New Oral Anticoagulants vs. Warfarin for post Cardiac Surgery Atrial Fibrillation. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	5

#	Article	IF	CITATIONS
181	Associations Between Alcohol Intake and Genetic Predisposition With Atrial Fibrillation Risk in a National Biobank. Circulation Genomic and Precision Medicine, 2020, 13, e003111.	3.6	4
182	Temporal trends in cause-specific mortality among individuals with newly diagnosed atrial fibrillation in the Framingham Heart Study. BMC Medicine, 2021, 19, 170.	5.5	4
183	Comparative Effectiveness of Implantable Defibrillators for Asymptomatic Brugada Syndrome: A Decisionâ€Analytic Model. Journal of the American Heart Association, 2021, 10, e021144.	3.7	4
184	Comparative Clinical Effectiveness of Populationâ€Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decisionâ€Analytic Model. Journal of the American Heart Association, 2021, 10, e020330.	3.7	4
185	Outpatient Prescription Practices in Patients with Atrial Fibrillation (From the NCDR PINNACLE) Tj ETQq $1\ 1\ 0$.	784314 rgBT 1.6	/Oyerlock I
186	Somatic Mutations and Atrial Fibrillation. Circulation: Cardiovascular Genetics, 2015, 8, 2-3.	5.1	3
187	Should This Patient Be Screened for Atrial Fibrillation?. Annals of Internal Medicine, 2019, 171, 828.	3.9	3
188	Deep learning to estimate cardiac magnetic resonance–derived left ventricular mass. Cardiovascular Digital Health Journal, 2021, 2, 109-117.	1.3	3
189	Usefulness of Rhythm Monitoring Following Acute Ischemic Stroke. American Journal of Cardiology, 2021, 147, 44-51.	1.6	3
190	Approximate conditional phenotype analysis based on genome wide association summary statistics. Scientific Reports, 2021, 11, 2518.	3.3	3
191	ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor. American Heart Journal, 2022, 249, 76-76.	2.7	3
192	Abstract 12922: Electrocardiogram-Based Deep Learning and Clinical Risk Factors to Predict Incident Atrial Fibrillation. Circulation, 2021, 144, .	1.6	3
193	Deep learning on resting electrocardiogram to identify impaired heart rate recovery. Cardiovascular Digital Health Journal, 2022, 3, 161-170.	1.3	3
194	ECG monitoring after acute ischemic stroke. Neurology, 2019, 92, 65-66.	1,1	2
195	The Implementation and Acceptability of a Mobile Application for Screening for Atrial Fibrillation at Home. Telemedicine Journal and E-Health, 2021, 27, 1305-1310.	2.8	2
196	Case 10-2022: A 78-Year-Old Man with Marked Ventricular Wall Thickening. New England Journal of Medicine, 2022, 386, 1266-1276.	27.0	2
197	Response by Lubitz et al to Letter Regarding Article, "Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study― Stroke, 2017, 48, e143.	2.0	1
198	Secondary Precipitants of Atrial Fibrillation and Anticoagulation Therapy. Journal of the American Heart Association, 2021, 10, e021746.	3.7	1

#	Article	IF	CITATIONS
199	Point-of-care screening for atrial fibrillation: Where are we, and where do we go next?. Cardiovascular Digital Health Journal, 2021, 2, 294-297.	1.3	1
200	Abstract 192: Comparative Clinical Effectiveness of Population-based Atrial Fibrillation Screening Using Wearable Devices: A Decision-Analytic Model. Circulation, 2020, 142, .	1.6	1
201	Ventricular arrhythmia management in patients with genetic cardiomyopathies. Heart Rhythm O2, 2021, 2, 819-831.	1.7	1
202	Cascade testing for inherited cardiac conditions: Risk perception and screening after a negative genetic test result. Journal of Genetic Counseling, 0, , .	1.6	1
203	Genetics, Exercise, and Early-Onset Arrhythmogenic Right Ventricular Cardiomyopathy. JACC: Clinical Electrophysiology, 2015, 1, 561-562.	3.2	Ο
204	Clockwork and Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. JACC: Clinical Electrophysiology, 2017, 3, 1318-1320.	3.2	0
205	Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2020, 142, .	1.6	Ο
206	Abstract 13588: Cardiovascular Outcomes in Patients With Established Atherosclerosis and LDLR Loss of Function: Results From the FOURIER Trial. Circulation, 2020, 142, .	1.6	0
207	Abstract 14156: Automated Electronic Medical Record Mapping to Identify Acute Precipitants of Atrial Fibrillation and Oral Anticoagulation Use. Circulation, 2020, 142, .	1.6	Ο
208	Genetic Association of Body Mass Index With Pathologic Left Ventricular Remodeling. Journal of the American Heart Association, 2022, 11, e024408.	3.7	0
209	Abstract 10587: Frequency and Outcomes of Bradyarrhythmias in the Community. Circulation, 2021, 144,	1.6	Ο
210	Abstract 10816: Causal Effect of Atrial Fibrillation on Cardiovascular Diseases - A Mendelian Randomization Analysis in the Million Veteran Program. Circulation, 2021, 144, .	1.6	0
211	Abstract 11229: Clinical and Genetic Atrial Fibrillation Risk and Discrimination of Cardioembolic from Non-Cardioembolic Stroke. Circulation, 2021, 144, .	1.6	0
212	Abstract 13271: Combined Assessments of Monogenic and Polygenic Risk for Dilated Cardiomyopathy. Circulation, 2021, 144, .	1.6	0
213	Abstract 12224: Predictive Power and Value of a CAD Polygenic Risk Score in Primary Prevention Based on Age and Clinical Risk. Circulation, 2021, 144, .	1.6	0
214	Abstract 9757: Frequency of Atrial Fibrillation in a Contemporary Elderly Primary Care Population: A Vital-af Trial Study. Circulation, 2021, 144, .	1.6	0
215	Abstract 12176: Oral Anticoagulant Therapy Following Single-Lead ECG Screening Among Older Patients With Atrial Fibrillation: The VITAL-AF Trial. Circulation, 2021, 144, .	1.6	0
216	Abstract 13373: Cost-Effectiveness of Population-Based Atrial Fibrillation Screening Using Wearable Devices. Circulation, 2021, 144, .	1.6	0